

Supplementary Table 3. Risk factors of infliximab use in ulcerative colitis patients

Characteristic	Univariate analysis		Multivariate analysis	
	7-Year cumulative rate, %	p value	HR (95% CI)	p value
Baseline at diagnosis				
Age, yr		0.000		
≥ 20	5.8		Reference	
< 20	14.5		3.37 (1.61–7.04)	0.001
Sex		0.070		
Female	5.0		Reference	
Male	7.1		1.54 (0.86–2.74)	0.147
Body mass index, kg/m ²		0.122		
≥ 23	6.6		Reference	
< 23	7.4		1.40 (0.78–2.53)	0.258
Family history of IBD		0.228		
No	7.6		Reference	
Yes	13.0		1.82 (0.42–7.96)	0.428
Smoking status		0.550		
No	10.3		Reference	
Yes	7.4		1.11 (0.54–2.19)	0.775
Disease activity at diagnosis		0.000		
Mild	4.0		Reference	
Moderate	17.5		3.00 (1.58–5.73)	0.001
Severe	13.7		2.52 (1.08–5.90)	0.034
Montreal classification of extent of UC		0.000		
E1 (ulcerative proctitis)	2.0		Reference	
E2 (left-sided UC)	9.8		1.43 (0.58–3.51)	0.437
E3 (extensive UC)	8.9		1.39 (0.54–3.56)	0.495
Treatment				
UC-related admission		0.000		
No	2.0		Reference	
Yes	12.3		1.17 (0.48–2.89)	0.729
UC-related operation		0.124		
No	6.5		Reference	
Yes	1.7		0.14 (0.02–1.02)	0.069
Medication				
Oral steroids		0.067		
No	4.6		Reference	
Yes	8.0		1.49 (0.80–2.79)	0.210
IV steroids		0.000		
No	2.8		Reference	
Yes	22.0		2.01 (1.09–3.69)	0.024
Immunosuppressants		0.000		
No	0.6		Reference	
Yes	17.3		12.29 (4.70–32.11)	0.000

HR, hazard ratio; CI, confidence interval; IBD, inflammatory bowel disease; UC, ulcerative colitis; IV, intravenous.